review · Health Sciences Review
Interstitial Lung Diseases (ILDs) encompass a diverse group of disorders characterised by inflammation and fibrosis, leading to significant impairment in lung function and quality of life. With the increasing prevalence of ILDs, managing these conditions has become a pressing medical and economic challenge. Oxygen therapy is crucial in ILD management, offering benefits beyond hypoxemia correction, including symptom relief and potential influence on disease progression. However, patient compliance, long-term use, side effects, and the psychosocial impact of therapy present ongoing challenges. This narrative review examines the critical role of oxygen therapy in ILDs, highlighting its current applications, associated challenges, and emerging innovations such as targeted therapies, personalized oxygen delivery, and advancements in technology that promise to enhance patient care in this complex field.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1016/j.hsr.2024.100202
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
